Literature DB >> 30413623

Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication.

Ina Klusmann1, Kai Wohlberedt1, Anna Magerhans1, Federico Teloni2, Jan O Korbel3, Matthias Altmeyer2, Matthias Dobbelstein4.   

Abstract

The p53-Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is a modifier of chromatin, modulating polycomb repressor complex (PRC)-driven histone modifications. Here we show that, similar to Mdm2 knockdown, the depletion of PRC members impairs DNA synthesis, as determined in fiber assays. In particular, the ubiquitin ligase and PRC1 component RNF2/Ring1B is required to support DNA replication, similar to Mdm2. Moreover, the Ring finger domain of Mdm2 is not only essential for its ubiquitin ligase activity, but also for proper DNA replication. Strikingly, Mdm2 overexpression can rescue RNF2 depletion with regard to DNA replication fork progression, and vice versa, strongly suggesting that the two ubiquitin ligases perform overlapping functions in this context. H2A overexpression also rescues fork progression upon depletion of Mdm2 or RNF2, but only when the ubiquitination sites K118/K119 are present. Depleting the H2A deubiquitinating enzyme BAP1 reduces the fork rate, suggesting that both ubiquitination and deubiquitination of H2A are required to support fork progression. The depletion of Mdm2 elicits the accumulation of RNA/DNA hybrids, suggesting R-loop formation as a mechanism of impaired DNA replication. Accordingly, RNase H overexpression or the inhibition of the transcription elongation kinase CDK9 each rescues DNA replication upon depletion of Mdm2 or RNF2. Taken together, our results suggest that chromatin modification by Mdm2 and PRC1 ensures smooth DNA replication through the avoidance of R-loop formation.

Entities:  

Keywords:  Mdm2; RNF2; histone; p53; ubiquitin

Mesh:

Substances:

Year:  2018        PMID: 30413623      PMCID: PMC6275510          DOI: 10.1073/pnas.1809592115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  A rapid and efficient method to purify proteins at replication forks under native conditions.

Authors:  Kai Him Thomas Leung; Mohamed Abou El Hassan; Rod Bremner
Journal:  Biotechniques       Date:  2013-10       Impact factor: 1.993

Review 2.  A new world of Polycombs: unexpected partnerships and emerging functions.

Authors:  Yuri B Schwartz; Vincenzo Pirrotta
Journal:  Nat Rev Genet       Date:  2013-11-12       Impact factor: 53.242

3.  DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression.

Authors:  Stephanie Hampp; Tina Kiessling; Kerstin Buechle; Sabrina F Mansilla; Jürgen Thomale; Melanie Rall; Jinwoo Ahn; Helmut Pospiech; Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-12       Impact factor: 11.205

4.  The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis.

Authors:  D R Brown; C A Thomas; S P Deb
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

5.  Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.

Authors:  Katharina Schlacher; Nicole Christ; Nicolas Siaud; Akinori Egashira; Hong Wu; Maria Jasin
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

6.  EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

Authors:  Beatrice Rondinelli; Ewa Gogola; Hatice Yücel; Alexandra A Duarte; Marieke van de Ven; Roxanne van der Sluijs; Panagiotis A Konstantinopoulos; Jos Jonkers; Raphaël Ceccaldi; Sven Rottenberg; Alan D D'Andrea
Journal:  Nat Cell Biol       Date:  2017-10-16       Impact factor: 28.824

7.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

8.  Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.

Authors:  Koji Itahana; Hua Mao; Aiwen Jin; Yoko Itahana; Hilary V Clegg; Mikael S Lindström; Krishna P Bhat; Virginia L Godfrey; Gerard I Evan; Yanping Zhang
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

9.  UV-triggered p21 degradation facilitates damaged-DNA replication and preserves genomic stability.

Authors:  Sabrina F Mansilla; Gastón Soria; María Belén Vallerga; Martín Habif; Wilner Martínez-López; Carol Prives; Vanesa Gottifredi
Journal:  Nucleic Acids Res       Date:  2013-05-30       Impact factor: 16.971

10.  RNA/DNA Hybrid Interactome Identifies DXH9 as a Molecular Player in Transcriptional Termination and R-Loop-Associated DNA Damage.

Authors:  Agnese Cristini; Matthias Groh; Maiken S Kristiansen; Natalia Gromak
Journal:  Cell Rep       Date:  2018-05-08       Impact factor: 9.423

View more
  18 in total

1.  Mdm4 supports DNA replication in a p53-independent fashion.

Authors:  Kai Wohlberedt; Ina Klusmann; Polina K Derevyanko; Kester Henningsen; Josephine Ann Mun Yee Choo; Valentina Manzini; Anna Magerhans; Celeste Giansanti; Christine M Eischen; Aart G Jochemsen; Matthias Dobbelstein
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

2.  BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability.

Authors:  Shin-Ai Lee; Daye Lee; Minhwa Kang; Sora Kim; Su-Jung Kwon; Han-Sae Lee; Hye-Ran Seo; Prashant Kaushal; Nam Soo Lee; Hongtae Kim; Cheolju Lee; Jongbum Kwon
Journal:  Cell Death Differ       Date:  2022-05-30       Impact factor: 15.828

3.  RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity.

Authors:  Zhuo Zhang; Lin Luo; Chuan Xing; Yu Chen; Peng Xu; Mao Li; Ling Zeng; Chao Li; Sadashib Ghosh; Deborah Della Manna; Tim Townes; William J Britt; Narendra Wajapeyee; Barry P Sleckman; Zechen Chong; Jianmei Wu Leavenworth; Eddy S Yang
Journal:  Nat Cancer       Date:  2021-10-22

Review 4.  Sources, resolution and physiological relevance of R-loops and RNA-DNA hybrids.

Authors:  Eva Petermann; Li Lan; Lee Zou
Journal:  Nat Rev Mol Cell Biol       Date:  2022-04-22       Impact factor: 113.915

Review 5.  Walking a tightrope: The complex balancing act of R-loops in genome stability.

Authors:  Joshua R Brickner; Jada L Garzon; Karlene A Cimprich
Journal:  Mol Cell       Date:  2022-05-03       Impact factor: 19.328

Review 6.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

Review 7.  The Ubiquitin Proteasome System in Genome Stability and Cancer.

Authors:  Jonathan J Morgan; Lisa J Crawford
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

8.  Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.

Authors:  Viola Ellison; George K Annor; Clara Freedman; Gu Xiao; Devon Lundine; Elzbieta Freulich; Carol Prives; Jill Bargonetti
Journal:  Oncotarget       Date:  2021-06-08

Review 9.  Histone dynamics during DNA replication stress.

Authors:  Chia-Ling Hsu; Shin Yen Chong; Chia-Yeh Lin; Cheng-Fu Kao
Journal:  J Biomed Sci       Date:  2021-06-19       Impact factor: 8.410

Review 10.  Mdm2: Open questions.

Authors:  Matthias Dobbelstein; Arnold J Levine
Journal:  Cancer Sci       Date:  2020-06-11       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.